Hold Sun Pharmaceutical Industries; target of Rs 700: ICICI Direct
ICICI Direct recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 700 in its research report dated May 28, 2021.01-06-2021
01-06-2021
Buy Sun Pharmaceutical Industries: target of Rs 810: Sharekhan
Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 810 in its research report dated May 27, 2021.31-05-2021
Sun Pharma: Traction in speciality likely to sustain
Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well31-05-2021
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / Institutional Investor Meeting with the Company29-05-2021
Sun Pharma joins biosimilars race, to target assets with patent expiries in 7-10 years
Company chief Dilip Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars but now aims to spend between 8-9 percent of turnover on RD.28-05-2021
Positive speciality portfolio outlook bodes well for Sun Pharma
The management has highlighted that speciality business revenues grew helped by rising sales of products such as psoriasis treatment Ilumya, ophthalmology drug Cequa, and acne treatment Absorica.28-05-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Acquisition Of Trademarks And Patent License For Dapagliflozin And Its Combinations From Astrazeneca AB By Sun Pharma And Its Subsequent Change In Business Relationship Under The Distribution Services Agreement,2016 With Astrazeneca Pharma India Ltd
As per letter attached.28-05-2021
Earnings Call for Q4FY21 of Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript.27-05-2021
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financial results for the fourth quarter and full year ending March 31st, 2021.full-year27-05-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board approves Dividend
As per letter attached27-05-2021